Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2)

Next Previous
Trial Profile

Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Irinotecan; Paclitaxel
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms ORIENT-2
  • Sponsors Cinda Biopharmaceutical; Innovent Biologics

    • Most Recent Events

    • 15 Nov 2021 Results (N=1683) of meta-analysis and systematic review evaluating the efficacy and safety of PD-1 inhibitors monotherapy versus chemotherapy in second-line treatment of AEC published in the Clinical Therapeutics
    • 31 May 2020 Results evaluating the efficacy and safety of sintilimab in patients with advanced esophageal squamous cell carcinoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 According to an Innovent Biologics media release, results (as of 2nd Aug 2019) from this study were presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract # 4511, Poster # 119, Friday, 29th May, 2020).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top